Puri Pharmaceuticals improves its intermediate industry layout

In the entire pharmaceutical industry chain of "API-Intermediates-Formulation," pharmaceutical intermediates are a crucial link in ensuring product quality and cost advantages. Since its establishment in 2004, Henan PURUI Pharmaceutical Co., Ltd. has continuously increased its investment in the independent research and development and production of key intermediates. It has now established multiple high-yield, low-pollution, and scalable intermediate synthesis production lines, strongly supporting the large-scale production of its anticholinergic and emergency APIs.

PURUI Pharmaceutical's intermediate business covers the entire process from laboratory pilot-scale trials to commercial production. The company is equipped with advanced synthesis reactors, separation and purification equipment, and cleanrooms, enabling it to provide customized intermediate synthesis services from gram-scale to ton-scale according to customer needs. Simultaneously, relying on its R&D subsidiary, PURE Pharmaceutical can undertake intermediate process development, process optimization, and technology transfer projects, providing efficient and compliant intermediate solutions for global innovative pharmaceutical companies.

Through a rigorous intermediate quality control system—including intermediate impurity profile analysis, stability studies, and multi-batch validation—PURE Pharmaceutical ensures the high quality and consistency of subsequent APIs and formulations. Currently, the company has achieved self-production and self-use of some key intermediates while also supplying them externally, effectively reducing the dependence on external suppliers for the entire industrial chain and enhancing the company's resilience in the global pharmaceutical supply chain.

"Intermediates are not just semi-finished products, but also the front line of quality control. We will continue to deepen the construction of our intermediate platform, create greener and more economical production processes, and generate greater value for domestic and international customers," said the head of production at PURE Pharmaceuticals.